Company news

MaxCyte, Inc. news in 2026

MaxCyte, Inc.'s news releases, calls and decks from 2026, newest first.

View company

MaxCyte to Participate in Three Upcoming Investor Conferences

October 28, 2026

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

October 14, 2026

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

September 23, 2026

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

August 19, 2026

MaxCyte Reports Second Quarter 2026 Financial Results

August 12, 2026

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

July 21, 2026

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

July 15, 2026

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

May 12, 2026

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

April 29, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 30, 2026

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

March 23, 2026

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

March 22, 2026

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

February 24, 2026

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

February 23, 2026

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

January 12, 2026

Calls in 2026

Decks in 2026